Clinical Trial Update: An Open Label, Safety Study to Assess the Potential for Adrenal Suppression [Phase 2]

View source ↗

Summary

Phase 2 open-label safety study assessing potential adrenal suppression in plaque psoriasis; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-06